CLINICAL TRIALS PROFILE FOR TRAVATAN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for TRAVATAN
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00670033 ↗ | Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension | Completed | Alcon Research | Phase 2 | 2008-04-01 | The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension. |
| New Formulation | NCT01452009 ↗ | Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004% | Withdrawn | Alcon Research | Phase 3 | 2011-11-01 | A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004% |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for TRAVATAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00047554 ↗ | Study of TRAVATAN in Subjects With Iris Pigmentation Changes | Terminated | Alcon Research | 2003-05-01 | The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN. | |
| NCT00051155 ↗ | A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT) | Completed | Alcon Research | Phase 3 | 2001-01-01 | To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension. |
| NCT00051168 ↗ | A Long-term Safety Study of Once-daily Travatan | Completed | Alcon Research | Phase 3 | 2006-01-01 | Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension. |
| NCT00061503 ↗ | Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension | Completed | Alcon Research | Phase 4 | 2003-04-01 | The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT). |
| NCT00121147 ↗ | Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan | Completed | Alcon Research | N/A | 2003-09-01 | The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRAVATAN
Condition Name
Clinical Trial Locations for TRAVATAN
Trials by Country
Clinical Trial Progress for TRAVATAN
Clinical Trial Phase
Clinical Trial Sponsors for TRAVATAN
Sponsor Name
